Medical devices, healthcare technology and the business of care
510(k) clearance · K262775

AquaVance Clear Fluoride Treatment

The Belport Company Inc., DBA Gingi-Pak · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONK262775

What did the FDA decide?

The FDA recorded a substantially equivalent decision for K262775, AquaVance Clear Fluoride Treatment, submitted by The Belport Company Inc., DBA Gingi-Pak. The decision carries a date of 2026-10-27 and appears in the agency's list of 510(k) final decisions. The device is classified under product code LBH within the dental specialty. Substantial equivalence in the 510(k) pathway indicates clearance to market, not approval of a premarket approval application.

The source record identifies the device by name and applicant only. It does not describe the device's components, formulation, intended use, or the predicate device it was compared against, and no summary or statement is included. Whether this submission represents an original clearance or a change to a previously cleared device is not stated. Those details would need to be confirmed in the underlying FDA decision documents rather than inferred from the listing.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Dental
Decision date
Oct 27, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262775
Regulatory pathway
510(k) premarket notification
Product code
LBH
Decision code
SESE
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Varnish, Cavity.

Product code
LBH
FDA device class
2

FDA decision timeline

  1. K262775 received

    Application receipt date recorded by FDA.

  2. K262775 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LBH

Product / regulatory recordCompanyPathwayDecision dateSource
Kettenbach GmbH & Co. KG510(k) clearanceSep 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

The Belport Company Inc., DBA Gingi-Pak

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Camarillo, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records